Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
308 GBX | -0.65% | +1.32% | +8.83% |
04-26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
04-26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.83% | 3.33B | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Hutchmed Commences Phase I Trial of Tumor Drug Candidate HMPL-653 in China